7470-78-2

Basic information

• Product Name: methyl 4-[2-(4-chlorophenyl)-2-cyano-ethenyl]benzoate
• Synonyms: methyl 4-[2-(4-chlorophenyl)-2-cyano-ethenyl]benzoate
• CAS NO: 7470-78-2
• Molecular Formula: C₁₇H₁₂ClNO₂
• Molecular Weight: 297.74
• Mol File: 7470-78-2.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 445.5°C at 760 mmHg
• Flash Point: 223.3°C
• Appearance: /
• Density: 1.263g/cm³
• Vapor Pressure: 3.92E-08mmHg at 25°C
• Refractive Index: 1.626
• CAS DataBase Reference: methyl 4-[2-(4-chlorophenyl)-2-cyano-ethenyl]benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 4-[2-(4-chlorophenyl)-2-cyano-ethenyl]benzoate(7470-78-2)
• EPA Substance Registry System: methyl 4-[2-(4-chlorophenyl)-2-cyano-ethenyl]benzoate(7470-78-2)

Safety Data

• Hazardous Substances Data: 7470-78-2(Hazardous Substances Data)

Usage

InChI:InChI=1/C17H12ClNO2/c1-21-17(20)14-4-2-12(3-5-14)10-15(11-19)13-6-8-16(18)9-7-13/h2-10H,1H3

Upstream product

• 1571-08-0 methyl 4-formylbenzoate 
• 140-53-4 p-chlorobenzyl cyanide 

Relevant articles and documents

Human glucagon receptor antagonists with thiazole cores. A novel series with superior pharmacokinetic properties

The aim of the work presented here was to design and synthesize potent human glucagon receptor antagonists with improved pharmacokinetic (PK) properties for development of pharmaceuticals for the treatment of type 2 diabetes. We describe the preparation of compounds with cyclic cores (5-aminothiazoles), their binding affinities for the human glucagon and GIP receptors, as well as affinities for rat, mouse, pig, dog, and monkey glucagon receptors. Generally, the compounds had slightly less glucagon receptor affinity compared to compounds of the previous series, but this was compensated for by much improved PK profiles in both rats and dogs with high oral bioavailabilities and sustained high plasma exposures. The compounds generally showed species selectivity for glucagon receptor binding with poor affinities for the rat, mouse, rabbit, and pig receptors. However, dog and monkey glucagon receptor affinities seem to reflect the human situation. One compound of this series, 18, was tested intravenously in an anesthetized glucagon-challenged monkey model of hyperglucagonaemia and hyperglycaemia and was shown dose-dependently to decrease glycaemia. Further, high plasma exposures and a long plasma half-life (5.2 h) were obtained.